WZTL-002 CAR T-cells

Phase 2Cell therapy

MMalaghan Institute of Medical Research

WZTL-002 CAR T-cells is one of 27 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

WZTL-002 CAR T-cells

MMalaghan Institute of Medical Research

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Lymphoma

NCT06486051

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Recruiting·MMalaghan Institute of Medical Research·Phase 2·NCT06486051·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for WZTL-002 CAR T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WZTL-002 CAR T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WZTL-002 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Malaghan Institute of Medical Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MMalaghan Institute of Medical Research

WZTL-002 CAR T-cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News